Skip to content
Pharma Observatory a Scientist.com platform
  • Trial site

Trial site location from the registry's own city and country. GeoNames (geonames.org).

Clinical trial site

Kootenai Clinic Cancer Services - Post Falls

Kootenai Clinic Cancer Services - Post Falls in Post Falls, Idaho, United States is listed as a site for 271 registered clinical trials, 223 of them ongoing.

Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Registered trials 271
Ongoing 223

This page covers the site record Kootenai Clinic Cancer Services - Post Falls in Post Falls, Idaho, United States: the trials that list it by this name in ClinicalTrials.gov. The same place can be registered under other names, each with its own page and its own trials, and a count here is a number of registered trials, not of patients enrolled.

Get the Kootenai Clinic Cancer Services - Post Falls report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Trials by phase

Registered trials that list this site, by trial phase. 271 trials counted.

  • Phase 1 2 trials
  • Phase 1/2 5 trials
  • Phase 2 107 trials
  • Phase 2/3 19 trials
  • Phase 3 119 trials
  • Not applicable 12 trials
  • Observational 7 trials

Trials by status

The registry's own status summary: Ongoing, Completed, Terminated or Other.

  • Ongoing 223 trials
  • Completed 32 trials
  • Terminated 12 trials
  • Other 4 trials

Trials over time

Trials registered with a start date in each year, 1990 onward, most recent years first.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Not applicable
  • Observational

Top of scale: 27

2005: 1 trials (Phase 3 1) 2006: 1 trials (Phase 3 1) 2007: 1 trials (Phase 3 1) 2008: 3 trials (Phase 3 2, Phase 2 1) 2009: 5 trials (Not applicable 1, Phase 3 4) 2010: 5 trials (Phase 3 3, Phase 2 1, Phase 1/2 1) 2011: 9 trials (Phase 3 6, Phase 2 2, Phase 1/2 1) 2012: 4 trials (Phase 3 3, Phase 2 1) 2013: 4 trials (Phase 3 1, Phase 2 3) 2014: 14 trials (Not applicable 1, Phase 3 7, Phase 2/3 2, Phase 2 3, Phase 1/2 1) 2015: 13 trials (Observational 1, Phase 3 4, Phase 2/3 1, Phase 2 6, Phase 1/2 1) 2016: 8 trials (Phase 3 3, Phase 2 5) 2017: 15 trials (Phase 3 7, Phase 2/3 1, Phase 2 7) 2018: 21 trials (Not applicable 1, Phase 3 8, Phase 2/3 1, Phase 2 10, Phase 1 1) 2019: 27 trials (Observational 1, Not applicable 1, Phase 3 12, Phase 2/3 4, Phase 2 9) 2020: 24 trials (Observational 2, Phase 3 10, Phase 2/3 1, Phase 2 10, Phase 1 1) 2021: 16 trials (Observational 1, Phase 3 6, Phase 2 9) 2022: 17 trials (Observational 1, Not applicable 2, Phase 3 3, Phase 2/3 3, Phase 2 8) 2023: 20 trials (Not applicable 1, Phase 3 8, Phase 2/3 2, Phase 2 8, Phase 1/2 1) 2024: 26 trials (Not applicable 2, Phase 3 6, Phase 2/3 3, Phase 2 15) 2025: 24 trials (Observational 1, Not applicable 1, Phase 3 16, Phase 2/3 1, Phase 2 5)

Trials that list this site and are registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 11
2025 24
2024 26
2023 20
2022 17
2021 16
2020 24
2019 27
2018 21
2017 15

2026 is partial: trials registered with a 2026 start date so far, not a full year. 2 trials are registered to start in 2027 or later, and not listed here

Recent trials

The newest registered trials that list this site. Each title opens its ClinicalTrials.gov record.

Source: ClinicalTrials.gov

Lead sponsors

Most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Conditions studied

The specific conditions of the trials that list this site, most trials first.